Frequently Asked Questions
-
Who is Bionavix?
Bionavix is a compliance-focused, white-glove enablement partner that helps hospitals and practices simplify and strengthen graft access. By combining a multi-manufacturer portfolio with structured systems, process discipline, and logistics expertise, we give clinicians confidence in every case. Our focus is on compliance, efficiency, and seamless support, allowing busy practices to reduce disruption and keep their attention where it belongs—on patient care.
-
What product types do you carry?
We carry a complete portfolio of Amniotic and Synthetic Skin Substitutes designed to fit almost any formulary, including acellular dermal matrices, amniotic membrane grafts, synthetic matrices products (availability varies by region/contract).
-
How is Bionavix different from other distributors?
Bionavix is not a skin substitute reseller. While many distributors focus on transactions, we also focus on enablement—equipping practices with training, payer resources, audit resources, and responsive logistics. Our approach ensures practices have the tools, education, and continuity they need to provide wound care with confidence.
-
Do you provide training and case support?
Yes. In-services, quick-reference handling/prep, and on-call case support for early use or new staff. Materials align to manufacturer Instructions for Use (IFU). (See FDA IFU guidance.)
-
Can you help with reimbursement and coding?
We can provide references for payer-aligned billing and coding specialists, and additional resources to assist with whatever questions you may have. See here for more information about our business, compliance, and audit resources.
-
Are you tied to a single manufacturer?
No. We’re portfolio-neutral or agnostic. Our role is to match practices and hospitals with the products that best suit your formulary, your patients, and your clinical needs. We do not push a single brand. We want to align with your clinical needs.
-
What documentation do you include with product?
IFU, lot/serial, usage logs when applicable, and approval/labeling references. IFU includes the official preparation, administration and handling instructions from the manufacturer under the FDA framework.
How to get started? That’s easy!
Drop us an email here with baselines about your practice and patient demographics. We’ll assign a support lead to reach out the same business day to collect initial onboarding intel including:
(1) brief discovery
(2) product/formulary alignment
(3) documentation & ordering setup
(4) staff in-service
(5) first-case readiness check
(6) first claim review
Business & Audit Support
-
Phone or email ordering via a simple form; you will also have direct access to a personal account lead who manages all your programmatic ordering. Where systems permit, we offer EHR-friendly order sets/preference cards.
-
If you haven’t used skin substitutes recently, we’re happy to walk you through things. Our first step is to review compliance requirements together and connect your team with the tools and resources that set you up for success.
Next, we’ll work with you to select a product that fits your clinical needs and patient profile. From there, we’ll guide you through “The Process” — the Bionavix framework for integrating skin substitutes. That begins with one patient and one graft, so your team can see the workflow in action from start to finish.
We keep this onboarding slow, methodical, and interactive so your staff has time to learn, ask questions, and build confidence at each step. The goal is simple: to help you re-enter wound care with clarity, compliance, and confidence.
-
Don’t worry, we’re not going anywhere, we stand ready to connect you with the resources you need to assist you through the process.cription
-
Often. We plan back-up SKUs and sizes, and can re-source quickly when cases shift. We’ll communicate promptly if constraints exist.
16) What’s your stance on “all products are the same”?
A: They’re not. Labeling, IFU, storage/handling, evidence, and policy treatment differ. Our value is helping you navigate those differences efficiently and compliantly. (U.S. Food and Drug Administration)
17) Will you disappear after the first order?
A: No. Our model is enablement: training refreshers, policy alerts, quarterly business reviews, and continuous support for staff transitions.
18) How do you handle returns or issues?
A: We follow manufacturer policy and applicable law—and we help document any issue (e.g., handling temperature, seal integrity) for swift resolution.
19) How do you protect data and patient privacy?
A: We operate to health-information privacy best practices and minimize PHI exposure in ordering/logistics; when PHI is necessary, we follow agreed safeguards and BAAs where appropriate.
20) How do we get started?
A: Simple onboarding: (1) brief discovery (indications, sites, payers), (2) product/formulary alignment, (3) documentation & ordering setup, (4) staff in-service, (5) first-case readiness check.
-
We monitor fee schedules and manufacturer status and alert you with margin-stability alternatives and playbooks to pivot calmly— proactively. (ASP/CMS updates & LCD context.)
-
We curate and summarize evidence in terms payers recognize (e.g., closure rates, time-to-closure, recurrence, adverse events, total cost-of-care) and point to relevant LCD language—without making new clinical claims.
-
We set defined delivery windows with proactive confirmations and contingency sourcing if something slips. For early starts/emergent cases, we support escalations where feasible (no absolute guarantees).
-
We follow manufacturer policy and applicable law—and we help document any issue (e.g., handling temperature, seal integrity) for swift resolution.
Change management
-
Don’t worry, we’re not going anywhere, we stand ready to connect you with the resources you need to assist you through the process.
-
Bionavix is built on the belief that loyalty runs both ways. We invest in our people with training, resources, and long-term development, and we extend that same loyalty to the practices we serve. Our goal is to be the partner you can rely on—not just for a case or a quarter, but for the long run. That commitment is visible in our service culture, our stability, and the continuity we provide even during industry disruption.
-
Healthcare policy is evolving, and reimbursement shifts are creating uncertainty. Many distributors wait until changes hit before responding—Bionavix is different. We monitor CMS and payer trends continuously, partner with external compliance experts, and communicate proactively with our practices. Our clients trust us because we prepare them before changes occur, giving them insight, resources, and confidence in navigating an uncertain environment.
-
The wound care market is volatile, and practices often experience sudden disruption when a manufacturer exits or a rep leaves. Bionavix was designed to prevent that. We source from multiple manufacturers, maintain ready-to-pivot product pathways, and support accounts through our inside sales and virtual support model. That means even when a supplier falters, our clients have continuity of product access, support, and training so patient care isn’t disrupted.
-
Compliance and integrity are at the heart of everything we do. Bionavix operates under the principle that if something doesn’t align with Centers for Medicare & Medicaid Services (CMS) guidelines, it doesn’t belong in our business. We work closely with external compliance experts, provide manufacturer-approved coding resources, and ensure our training reflects LCD and payer policy. This commitment protects physicians, staff, and patients by making sure our support is always grounded in integrity and transparency.
-
No. Our model is sales and enablement: training refreshers, policy alerts, quarterly business reviews, and continuous support for staff transitions. We work toward long term relationships, and have every intention of serving as your most valued and reliable partner for years to come.
-
We operate to health-information privacy best practices (HIPPA) and minimize PHI exposure in ordering/logistics; when PHI is necessary, we follow agreed safeguards and BAAs where appropriate.